Effect of serum tumor necrosis factor receptor-6 level on prognosis of AECOPD patients with respiratory failure / 中国医师杂志

Objective To study the expression of serum tumor necrosis factor receptor-6 (TR6) [decoy receptor 3 (DcR3)] in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated with respiratory failure,and to analyze its influence on prognosis.Methods 134 patients with AECOPD admitted to our hospital from March 2015 to March 2017 were selected as the study subjects.According to whether or not respiratory failure occurred,they were divided into respiratory failure group (65 cases) and non-respiratory failure group (69 cases).Another 60 healthy volunteers who underwent physical examination in our hospital during the same period were selected as the control group.Serum albumin (ALB),C-reactive protein (CRP),first-second forced breathing volume (FEV1％),first-second forced breathing vdume (FEV1/FVC),arterial partial oxygen pressure (PaO2) and arterial partial carbon dioxide pressure (PaCO2) were collected.Enzyme-linked immunosorbent assay (ELISA) was used to detect serum levels of interleukin-8 (IL-8),tumor necrosis factor-alpha (TNF-α) and DcR3.Results The levels of ALB,FEV1,FEV1/FVC and PaO2 in respiratory failure group were significantly lower than those in non-respiratory failure group and control group (P ＜ 0.05),and those in non-respiratory failure group were significantly lower than those in control group (P ＜ 0.05);the levels of CRP,PaCO2,IL-8,TNF-α and DcR3 in respiratory failure group were significantly higher than those in non-respiratory failure group and control group (P ＜ 0.05).The survival rate of high DcR3 level group was significantly lower than that of low DcR3 level group (P ＜ 0.05).High levels of TNF-α and DcR3 were independent risk factors for adverse prognosis of AECOPD patients with respiratory failure (P ＜ 0.05).Conclusions The high expression of DcR3 in serum of AECOPD patients with respiratory failure is an independent risk factor for adverse prognosis.

Effect of decoy receptor 3 gene on hepatocyte apoptosis / 临床肝胆病杂志

ObjectiveTo investigate the effect of decoy receptor 3 (DcR3) gene on hepatocyte apoptosis, as well as the possible mechanism of action of DcR3 in this process. MethodsThe human liver cell lines were cultured in vitro, and pEF1α-DcR3 transfection group, pEF1α-IRES transfection group, and negative control group were established. The pEF1α-IRES-DsRed-Express2-DcR3 eukaryotic expression vector was constructed and transfected into human liver cell lines for 36 hours. qRT-PCR was used to measure the mRNA expression of DcR3, Fas ligand (FasL), α-smooth muscle actin (α-SMA), and transforming growth factor-β1 (TGF-β1), Western blot was used to measure the change in the protein expression of DcR3, and flow cytometry was used to measure apoptosis. An analysis of variance was used for comparison of continuous data between groups, and the least significant difference t-test was used for comparison between any two groups. ResultsAfter human liver cell lines were transfected with pEF1α-DcR3 for 36 hours, the pEF1α-DcR3 transfection group showed significant increases in the mRNA and protein expression of DcR3 compared with the pEF1α-IRES transfection group and negative control group (F=33 1695 and 14154, all P＜0.01). Compared with the other two groups, the pEF1α-DcR3 transfection group showed significant reductions in the mRNA expression of FasL, α-SMA, and TGF-β1 (F=269 4518, 20 7904, and 80678, all P＜0.01), which suggested that DcR3 inhibited the expression of FasL, α-SMA, and TGF-β1. Compared with the pEF1α-IRES transfection group and negative control group, the pEF1α-DcR3 transfection group showed a significant reduction in apoptosis rate (F=55863, all P＜0.01). ConclusionDcR3 can inhibit hepatocyte apoptosis and downregulate the mRNA expression of FasL, α-SMA, and TGF-β1.

Research progress of decoy receptor 3 in cancer / 肿瘤研究与临床

Decoy receptor 3(DcR3) gene expresses highly in some malignant tumors,it involves cellular proliferation regulation, inhibition of apoptosis, immune escape and tumor angiogenesis by competitively blocking the Fas/FasL, LIGHT and TL1 A/DR3 signal pathway, therefore it deeply relates to the malignant tumors's generation and progression.DcR3 is supposed to be the new tumor-specific marker that may cast the light to the tumor generation,development,prevention,diagnosis,treatment,prognosis and effect observation.DcR3 is expected to be open a new chapter in clinical application.